Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Vericel Corporation VCEL
$32.23
-$0.75 (-2.33%)
На 18:00, 12 мая 2023
-0.71%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
1590919536.00000000
-
week52high
35.46
-
week52low
17.30
-
Revenue
164365000
-
P/E TTM
-95
-
Beta
1.76816600
-
EPS
-0.36000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 12:30
Описание компании
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| BTIG | Buy | Buy | 18 июл 2022 г. |
| SVB Leerink | Outperform | Outperform | 25 февр 2022 г. |
| Truist Securities | Buy | Buy | 21 дек 2021 г. |
| SVB Leerink | Outperform | Outperform | 05 авг 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 06 мая 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 10 ноя 2022 г. |
| BTIG | Neutral | Buy | 10 ноя 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 03 янв 2023 г. |
| Truist Securities | Hold | Hold | 20 дек 2022 г. |
| Truist Securities | Hold | Hold | 31 янв 2023 г. |
| HC Wainwright & Co. | Buy | 27 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| SIEGAL JONATHAN | D | 675 | 330 | 02 февр 2023 г. |
| Colangelo Dominick | D | 0 | 39938 | 10 янв 2023 г. |
| Colangelo Dominick | D | 157066 | 39938 | 10 янв 2023 г. |
| Colangelo Dominick | A | 197004 | 39938 | 10 янв 2023 г. |
| SIEGAL JONATHAN | D | 875 | 331 | 14 окт 2022 г. |
| SIEGAL JONATHAN | D | 2813 | 937 | 30 сент 2022 г. |
| SIEGAL JONATHAN | D | 927 | 276 | 30 сент 2022 г. |
| SIEGAL JONATHAN | A | 1203 | 937 | 30 сент 2022 г. |
| WRIGHT LISA | D | 867 | 433 | 01 июн 2022 г. |
| WRIGHT LISA | A | 2784 | 433 | 01 июн 2022 г. |
Новостная лента
Vericel Corporation (VCEL) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
10 мая 2023 г. в 10:41
Vericel Corporation (VCEL) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.15 per share a year ago.
Vericel to Report First-Quarter 2023 Financial Results on May 10, 2023
GlobeNewsWire
26 апр 2023 г. в 08:30
CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its first-quarter 2023 financial results on Wednesday, May 10, 2023. Vericel's management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights.
Vericel Corporation: A Promising Future In Advanced Cell Therapies
Seeking Alpha
02 апр 2023 г. в 09:14
The FDA's recent approval of NexoBrid for the treatment of burns is expected to drive revenue growth in 2023. Vericel's MACI autologous cell therapy product for knee cartilage defects is on track for a potential accelerated commercial launch in 2024.
Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Tuesday, March 7, 2023
GlobeNewsWire
28 февр 2023 г. в 08:30
CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will present at the Canaccord Genuity Musculoskeletal Conference. The presentation is scheduled to begin at 12:30 p.m. ET (9:30 a.m. PT) on Tuesday, March 7, 2023.
Vericel Corporation (VCEL) Q4 2022 Earnings Call Transcript
Seeking Alpha
23 февр 2023 г. в 14:55
Vericel Corporation (NASDAQ:VCEL ) Q4 2022 Earnings Conference Call February 23, 2023 8:30 AM ET Company Participants Eric Burns – Head-Financial Planning and Analysis and Investor Relations. Nick Colangelo – President and Chief Executive Officer Joe Mara – Chief Financial Officer Conference Call Participants Ryan Zimmerman – BTIG Sam Brodovsky – Truist Securities Jeffrey Cohen – Ladenburg Sean Lee – HC Wainwright Operator Ladies and gentlemen, thank you for standing by.